Cure8 research brief
TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new anti-fibrotic strategy.
Patients with stricturing Crohn's disease, IBD clinicians, fibrosis researchers, and drug developers
The authors measured TG2 expression and enzymatic activity in human strictured intestinal tissue and in human intestinal myofibroblasts (HIMF), finding higher TG2 activity in strictured Crohn's tissue that correlated with fibrosis severity.
Single-cell RNA sequencing localized TG2 production to myofibroblasts, and functional lab experiments showed selective TG2 inhibition lowered accumulation of fibronectin and several collagens by HIMF.
In mouse experiments, inducible global knockout of TGM2 (the gene encoding TG2) prevented experimental intestinal fibrosis without changing intestinal inflammation, supporting a fibrosis-specific role. The report presents TG2 as a potential anti-fibrotic therapeutic target, but clinical translation will require drug development and human trials.
Findings are based on human tissue analyses, cell experiments, sequencing data, and mouse knockout models reported in the article abstract. This is preclinical/early-stage translational work; clinical trials are needed before patient treatments emerge.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...
The study points to a specific immune cell type (pro-inflammatory CD4+ macrophages) and altered cellular interactions in rectal tissue that are linked to perianal fistulizing Crohn's disease, which may help explain...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
